Medical management of acute coronary syndromes

Journal of Interventional Cardiology

Volumn 12, Issue 1, 1999, Pages 33-49

  Talley, J David ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; NITRATE; PLACEBO; PLASMINOGEN ACTIVATOR; PROPRANOLOL; SARUPLASE; STREPTOKINASE; THROMBIN INHIBITOR; TIMOLOL; UROKINASE;

ANGINA PECTORIS; CLINICAL TRIAL; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

EID: 0033005231     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.1999.tb00208.x     Document Type: Review

References (129)

1. Chung S-J, Fung H-L. Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production: Probes with inhibitors and tolerance development. Biochem Pharmacol 1993;45:157-163.
2. Brown BG, Bolson EL, Peterson RB, et al. The mechanisms of nitroglycerin action. Stenosis vasodilatation as a major component of drug response. Circulation 1981;65:1089-1097.
3. The GISSI-3 Investigators. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1994;343:1115-1122.
4. Thadani U. Secondary preventive potential of nitrates in ischaemic heart disease. Eur Heart J 1996;17(Suppl F):30-36.
5. McClellan JR. Unstable angina: Prognosis, noninvasive risk assessment, and strategies for management. Clin Cardiol 1994;17:229-238.
6. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary. Circulation 1996;94:2341-2350.
7. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: Diagnosis and management. Clinincal Practice Guideline, Number 10. AHCPR Publication No. 94-0602. Rockville, Md: US Dept of Health and Human Services, 1994.
8. Frishman WH, Strom JA, Kirschner M, et al. Labetalol therapy in patients with systemic hypertension and angina pectoris: Effects of combined alpha and beta adrenoceptor blockade. Am J Cardiol 1981;48:917-928.
9. Anderson JL. Post-myocardial infarction trials: Beta-beta blockers, antiarrhythmics, thrombolytics. Control Clin Trials 1996;17:17S-27S.
10. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2:823.
11. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801.
12. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-1714.
13. Lau J, Antman EM, Jimanez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-254.
14. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997;80(Suppl 9B):35J-39J.
15. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-627.
16. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-beta blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-121.
17. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981;1:1225-1228.
18. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: A randomized, double-blind, placebo-controlled trial. Circulation 1986;73:331-337.
19. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: Findings from the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT). Am J Cardiol 1987;60:18A-25A.
20. Held PH, Yusuf S, Furberg CD. Calcium channel beta blockers in acute myocardial infarction and unstable angina: An overview. BMJ 1989;299:1187-1192.
21. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068-1073.
22. Gibson RS, Boden WE, Theraux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: Results of a double-blind, randomized multicenter trial. N Engl J Med 1986;315:423-429.
23. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.
24. Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: A randomized, double blind, placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Report of The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J 1986;56:400-413.
25. Muller JE, Turi ZG, Pearle DL, et al. Nifedipine and conventional therapy for unstable angina pectoris: A randomized, double-blind comparison. Circulation 1984;69:728-739.
26. Fang ZY, Picart N, Abramowicz M, et al. Intravenous diltiazem versus nitroglycerin for silent and symptomatic myocardial ischemia in unstable angina pectoris. Am J Cardiol 1991;68:42C-46C.
27. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
28. Boersma E, Maas ACP, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996;348:771-775.
29. Newby LK, Rutsch WR, Califf RM, et al, for the GUSTO-I Investigators. Time from symptom onset to treatment and outcomes after thrombolytic therapy. JACC 1996;27:1646-1655.
30. The LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-766.
31. The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314:1465-1471.
32. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
33. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
34. Boersma E, Simoons ML. Reperfusion strategies in acute myocardial infarction. Eur Heart J 1997;18:1703-1711.
35. Gulba DC, Bode C, Runge MS, et al. Thrombolytic agents-an overview. Ann Hematol 1996;73:S9-S27.
36. Staniforth DH, Smith RAG, Hibbs M. Streptokinase and anisoylated streptokinase plasminogen complex: Their action on hemostasis in human volunteers. Eur J Clin Pharmacol 1983;24:751-756.
37. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled trial. Lancet 1988;1:545-549.
38. Neuhaus KL, Tebbe U, Gottwik M, et al. Intravenous recombinant tissue plasminogen activator (rtPA) and urokinase in acute myocardial infarction: Results of the German Activator Urokinase Study (GAUS). JACC 1988;12:581-587.
39. Collen D, Vanderschueren S, Van de Werf F. Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Haemostasis 1996;26(Suppl 4):294-300.
40. TIMI Study Group. The Thrombolysis in Myocardial Infarction trial. N Engl J Med 1985;312:932-936.
41. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute infarction. Lancet 1993;339:753-770.
42. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI). GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
43. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
44. Collins R, Peto R, Baigent C, et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847-860.
45. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
46. Ross AM, Coyne KS, Moreyra E, et al, for the GUSTO-I Angiographic Investigators. Extended mortality benefit of early postinfarction reperfusion. Circulation 1998;97:1549-1556.
47. Barbagelata NA, Granger CB, Oqueli E, et al. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: A pooled analysis. Am Heart J 1997;133:273-282.
48. Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO-IIb trial. JACC 1998;31:1493-1498.
49. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-2732.
50. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898.
51. The INJECT Study Group. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet 1995;346:329-336.
52. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
53. Collen D, Stassen JM, Yasuda T, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994;72:98-104.
54. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator compared with front-loaded tissue plasminogen activator in acute myocardial infarction: Primary results of the TIMI 10B trial. Circulation 1997;96(Suppl I):I-206.
55. Lijnen HR, Van Hoef B, Collen D. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. Biochim Biophys Acta 1986;884:402-408.
56. Collen D, Stassen JM, Blaber M, et al. Biological and thrombolytic properties of proenzyme and active forms of human urokinase-III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemost 1984;52:27-30.
57. Loscalzo J, Wharton TP, Kirshenbaum JM, et al. Clot-selective coronary thrombolysis with pro-urokinase. Circulation 1989;79:776-782.
58. PRIMI Trial Study Group. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989;I:863-868.
59. Bär FW, Meyer J, Vermeer F, et al. Comparison of saruplase and alteplase in acute myocardial infarction: The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Am J Cardiol 1997;79:727-732.
60. Tebbe U, Michels R, Adgey J, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS Equivalence Trial. JACC 1998;31:487-493.
61. Vanderschueren S, Barrios L, Kerdsinchai P, et al. for the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044-2049.
62. Vanderschueren S, Dens J, Kerdsinchai P, et al. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 1997;134:213-219.
63. Collen D, Moreau H, Stockx L, et al. Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction. Circulation 1996;94:207-216.
64. Witt W, Maass B, Baldus B, et al. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994;90:421-426.
65. Bode C, Runge MS, Schönermark S, et al. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 1990;81:1974-1980.
66. Runge MS, Bode C, Matsueda GR, et al. Antibody-enhanced thrombolysis: Targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci U S A 1987;84:7659-7662.
67. Bode C, Matsueda G, Hui KY, et al. Antibody-directed urokinase: A specific fibrinolytic agent. Science 1985;229:765-767.
68. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811-2818.
69. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial. Circulation 1994; 89:1545-1556.
70. Owen J, Friedman KD, Grossman BA, et al. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988;72:616-620.
71. Merlini PA, Bauer KA, Oltrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. JACC 1995;25:203-209.
72. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence. Circulation 1998;97:211-218.
73. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
74. Mueller RL, Scheidt S. History of drugs for thrombotic disease. Circulation 1994;89:432-449.
75. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-805.
76. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998;316:1337-1343.
77. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-1111.
78. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.
79. Lewis HD, Daview JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403.
80. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-1375.
81. Thaulow E, Dale J, Myhre E. Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease. Am J Cardiol 1984;53:1255-1258.
82. The RAPT Investigators. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 1994;89:588-595.
83. Cattaneo M, Lombardi R, Bettega D, et al. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 1993;13:393-397.
84. Sivenius J, Puranen J. Antiplatelet therapy in secondary prevention of stroke: A review of efficacy and tolerability. CNS Drugs 1997;8:38-50.
85. Ferguson JJ III. New pharmacological adjuncts for coronary stenting: Can new anticoagulants improve outcomes? J Interven Cardiol 1997;10:155-159.
86. Mansoor GA, Aziz K. Delayed chronic diarrhea and weight loss possibly due to ticlopidine therapy. Ann Pharmacother 1997;31:870-872.
87. Neumann FJ, Hall D, Schömig A. Neutropenia with ticlopidine plus aspirin. Lancet 1997;349:1552-1553.
88. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
89. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505.
90. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
91. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
92. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-854.
93. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. JACC 1993;22:381-389.
94. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S-275S.
95. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials. BMJ 1996;313:652-659.
96. White HD. Is heparin of value in the management of acute myocardial infarction? Cardiovasc Drugs Ther 1997;11:111-119.
97. Schröder R. Pharmacological and invasive therapy for acute myocardial infarction. In: Willich SN, Muller JE, eds. Triggering of Acute Coronary Syndromes. Dordrecht, Netherlands: Kluwer Academic Publishers, 1996, pp. 331-346.
98. Krumholz HM, Hennen J, Ridker PM, et al. Use and effectiveness of intravenous heparin therapy for treatment of acute myocardial infarction in the elderly. JACC 1998;31:973-979.
99. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta analysis. JAMA 1996;276:811-815.
100. Cohen M, Parry G, Adams PC, et al. Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Eur Heart J 1994;15:1196-1203.
101. Cohen M, Adams PC, Hawkins L, et al. Usefulness of antithrombolic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol 1990;66:1287-1292.
102. Gurfinkel EP, Manos EJ, Mejafl RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. JACC 1995;26:313-318.
103. Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. JACC 1994;24:39-45.
104. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
105. Gallistl S, Muntean W, Leis HJ. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma. Thromb Haemost 1995;74:1163-1168.
106. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935.
107. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med 1989;40:31-44.
108. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis, frequency, avoidance and management. Drug Saf 1997;17:325-341.
109. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
110. Nurmohamed MT, ten Cate H, ten Cate JW. Low molecular weight heparin(oid)s: Clinical investigations and practical recommendations. Drugs 1997;53:736-751.
111. Weitz JI, Hirsh J. Overview of new developments in heparins, thrombin inhibitors, and other new and novel agents. In: Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker, 1997, pp. 77-86.
112. Glick A, Kornowski R, Michowich Y, et al. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996;77:1145-1148.
113. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
114. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-68.
115. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
116. Toschi V, Lettino M, Gallo R, et al. Biochemistry and biology of hirudin. Coron Artery Dis 1996;7:420-428.
117. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994;90:1624-1630.
118. Global Use of Strategies to Open Occluded Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
119. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer KrankenhausSrzte (ALKK). Circulation 1994;90:1638-1642.
120. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-921.
121. The Global Use of Strategies to Open Occluded Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
122. White HD, Aylward PE, Frey MJ, et al. A randomized, double-blind trial of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction: The Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 1997;96:2155-2161.
123. White HD. Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. Thromb Haemost 1997;78:364-366.
124. Andersen K, Dellborg M, Emanuelsson H, et al. Thrombin inhibition with inogatran for unstable angina pectoris: Evidence for reactivated ischaemia after cessation of short-term treatment. Coron Artery Dis 1996;7:673-681.
125. Fitzgerald D, Murphy N. Argatroban: A synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996;7:455-458.
126. Barsness GW, Barbeau G, Leimberger JD, et al. Potent, direct thrombin inhibition with efegratan does not improve residual infarct artery stenosis: Results from the PRIME trial. (abstract) Circulation 1997;96:I-206.
127. Sitko GR, Ramjit DR, Stabilito II, et al. Conjuctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 1992;85:805-815.
128. Hanson SR, Griffin JH, Harker LA, et al. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993;92:2003-2012.
129. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: Potential therapeutic applications. Thromb Haemost 1997;78:471-477.